This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication.

For a drug class this widely used, the relationship between GLP-1 medications and mental health has been surprisingly hard to pin down — some studies suggest a protective effect, others flag a drug-specific risk signal, and the honest answer as of mid-2026 is "it depends which drug, which comparison group, and which patient population you're looking at." A new real-world electronic health record study published this month adds an important, nuanced data point: semaglutide and tirzepatide generally showed lower hazards of anxiety and depression diagnoses than bariatric surgery or naltrexone-bupropion — but tirzepatide showed higher hazards of anxiety and insomnia than semaglutide in a specific subgroup (News-Medical.net coverage, July 1, 2026).

This guide walks through what the current body of research actually shows, why studies sometimes disagree, and what it means if you're managing anxiety, depression, or another mental health condition while on a GLP-1.

Why This Question Is Genuinely Complicated

Three different research methods have looked at this question and produced results that seem, at first glance, to conflict:

1. Randomized controlled trial post-hoc analyses (the gold standard for causation) generally find no increased risk, and sometimes a small protective signal. 2. Real-world electronic health record cohort studies (large populations, imperfect control for confounding) show mixed, drug-specific, and comparator-dependent results. 3. Pharmacovigilance / adverse event reporting databases (voluntary reports, cannot establish causation, but useful for signal detection) show a semaglutide-specific depression signal.

None of these methods is "wrong" — they're measuring different things with different strengths and limitations. Understanding which type of study you're reading is the key to not getting whiplash from seemingly contradictory headlines.

What the Newest Study Found (July 2026)

The Core Comparison

Individuals receiving semaglutide and tirzepatide generally had lower hazards of several recorded neuropsychiatric diagnoses compared with bariatric surgery recipients. Among individuals with obesity and type 2 diabetes specifically, both medications were associated with lower hazards of anxiety disorders, broadly defined cognitive deficits, mood disorders, and depression (News-Medical.net).

The Head-to-Head Exception

Among adults without type 2 diabetes, a direct tirzepatide-versus-semaglutide comparison found tirzepatide was associated with higher hazards of anxiety disorders and insomnia than semaglutide — with no consistent differences observed for most other neurological outcomes after statistical adjustment.

Versus Naltrexone-Bupropion

Compared with naltrexone-bupropion (an older weight-management medication with known psychiatric considerations), both semaglutide and tirzepatide were generally associated with lower hazards of anxiety and depression.

What This Pattern Suggests

The study's own conclusion: initiation of tirzepatide and semaglutide is associated with different neuropsychiatric outcome patterns depending on the comparator treatment and the presence of type 2 diabetes. In plain terms — there isn't one universal answer; it depends on what you're comparing against and who the patient is.

The Swedish Cohort Study: A Protective Signal in Diagnosed Patients

A separate, large national cohort study out of Sweden specifically examined patients already diagnosed with depression, anxiety, or both, and asked whether starting a GLP-1 receptor agonist changed their risk of their mental illness worsening (Taipale et al., 2026, The Lancet Psychiatry, PMID 41862258).

The Headline Numbers

  • Semaglutide: Hazard ratio 0.58 (95% CI 0.51–0.65) — a 42% reduction in risk of mental illness worsening.
  • Liraglutide: Hazard ratio 0.82 (95% CI 0.76–0.89) — a more modest but still significant protective association.
  • Exenatide and dulaglutide: No significant association in either direction.

Breaking Down Semaglutide's Effect by Condition

Semaglutide was specifically associated with decreased risk of worsening depression (HR 0.56), reduced anxiety worsening (HR 0.62), and lower risk of substance use disorder exacerbation (HR 0.53) in this cohort. As a therapeutic class, GLP-1 receptor agonists were also associated with reduced self-harm events (HR 0.56).

Why This Study Matters

This is one of the more reassuring data points available, specifically for patients who already carry a depression or anxiety diagnosis and are wondering whether starting a GLP-1 will make their psychiatric symptoms worse. The Swedish data suggests, if anything, the opposite may be more common — though individual response always varies.

The Trial Data: What Semaglutide's Own Post-Hoc Analysis Found

A post-hoc analysis of the STEP 1, 2, 3, and 5 randomized trials — published in JAMA Internal Medicine — specifically examined whether semaglutide 2.4 mg increased depression symptoms or suicidal ideation/behavior versus placebo, using validated tools (PHQ-9 for depression, C-SSRS for suicidality). The result: semaglutide was not associated with increased risk of depression symptoms or suicidal ideation/behavior relative to placebo, and was associated with a small, statistically significant — but not clinically meaningful — reduction in depressive symptoms.

This trial-level data is reassuring specifically because randomized trials control for confounding factors that observational studies cannot fully address.

The Signal Worth Knowing About: Adverse Event Reporting Data

What Pharmacovigilance Studies Found

Analyses of the FDA Adverse Event Reporting System (FAERS) and the WHO's VigiBase have identified a semaglutide-specific signal for depressive disorder reports — a reporting odds ratio of 1.26–1.38 depending on the database, with liraglutide and tirzepatide showing no equivalent signal in one 2025 analysis (pharmacovigilance study, PubMed). A separate FAERS-based analysis found signals for anxiety (PRR 1.34), depression (PRR 1.83), and suicidal ideation (PRR 3.44) specifically associated with semaglutide reports.

Why This Doesn't Contradict the Other Findings

Adverse event reporting databases capture voluntary reports, not population-level incidence — they're a signal-detection tool, not a measure of actual risk in the population. A drug that's prescribed to tens of millions of people will generate a large absolute number of reports for any condition, including ones that occur at baseline rates unrelated to the drug. These databases are genuinely useful for flagging things worth studying rigorously (like the NAION signal covered in our related GLP-1 vision risk article) — but they cannot, by design, establish causation the way the trial and cohort data above can.

What This Means If You Have Anxiety or Depression and Are Considering a GLP-1

The Reassuring Picture

The strongest-quality evidence available — randomized trial post-hoc analysis and the large Swedish cohort study — both suggest semaglutide is not associated with worsening depression or anxiety, and may even be associated with improvement in patients who already carry those diagnoses.

The Nuance Worth Discussing With Your Provider

If you're choosing between tirzepatide and semaglutide specifically, and you don't have type 2 diabetes, the July 2026 study's finding that tirzepatide showed higher anxiety and insomnia hazards than semaglutide in that population is worth raising directly with your prescriber — particularly if you have a pre-existing anxiety disorder.

What to Actually Monitor

Regardless of which GLP-1 you're on, track your mood and anxiety symptoms over the first several months, especially during dose escalation. Report any new or worsening psychiatric symptoms to your prescriber promptly — this is standard practice for any new medication affecting appetite and metabolism, not a GLP-1-specific concern.

The Bottom Line

As of mid-2026, the weight of evidence — spanning randomized trials, a large Swedish cohort study, and this month's EHR analysis — leans toward semaglutide having a neutral-to-protective relationship with anxiety and depression for most patients, with tirzepatide showing a more mixed picture that appears to depend on diabetes status and the specific comparison being made. This is an active area of research, and guidance may be refined as more prospective data becomes available.

Educational content only. Not medical advice. If you are experiencing thoughts of self-harm, contact the 988 Suicide & Crisis Lifeline (call or text 988) or seek emergency care immediately. Talk to your prescribing provider about your mental health history before starting or changing any GLP-1 medication.

Frequently Asked Questions

Does Ozempic or Wegovy cause depression or anxiety?

The strongest available evidence — a post-hoc analysis of the STEP randomized trials and a large Swedish cohort study — does not support this. Semaglutide was associated with reduced, not increased, hazards of depression and anxiety worsening in patients who already had those diagnoses.

Is tirzepatide worse for anxiety than semaglutide?

A July 2026 study found that among adults without type 2 diabetes, tirzepatide was associated with higher hazards of anxiety disorders and insomnia compared with semaglutide, head-to-head. This finding is worth discussing with your prescriber if you have a history of anxiety.

Can GLP-1 drugs actually improve depression or anxiety?

A large Swedish cohort study found semaglutide was associated with a 42% reduction in risk of mental illness worsening among patients already diagnosed with depression or anxiety (hazard ratio 0.58), suggesting a possible protective effect in that population, though this is observational data.

Why do some studies say GLP-1 drugs increase suicidal ideation risk?

Some pharmacovigilance analyses of voluntary adverse event reports have flagged a semaglutide-specific signal for suicidal ideation reports. These databases are useful for detecting signals worth studying further but cannot establish causation, unlike the randomized trial data, which found no increased suicidal ideation risk versus placebo.

Should I avoid GLP-1 medications if I have anxiety or depression?

Not based on current evidence. Discuss your specific history with your prescriber, but the strongest-quality studies available suggest semaglutide in particular is not associated with worsening these conditions and may be associated with improvement.

Is the mental health effect the same for all GLP-1 drugs?

No. The July 2026 study found different outcome patterns for semaglutide versus tirzepatide, and the Swedish cohort study found a stronger protective association for semaglutide than for liraglutide, with no significant association at all for exenatide or dulaglutide.

Sources

  1. News-Medical.net — Study links semaglutide and tirzepatide to fewer anxiety and depression diagnoses in obesity care: news-medical.net (July 1, 2026)news-medical.net
  2. Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. *The Lancet Psychiatry*, 2026 Apr;13(4):327-335. PMID 4186225841862258
  3. JAMA Network — Psychiatric Safety of Semaglutide for Weight Management (post-hoc analysis of STEP 1, 2, 3, 5 trials): jamanetwork.com (September 3, 2024)jamanetwork.com
  4. Pharmacovigilance study based on FAERS and VigiBase databases: PubMedPubMed